Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2] that targets IL-23.[3]
This drug was developed by MedImmune.
Immune activation: Dostarlimab Other: Ibalizumab
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 18.116.27.251